Beida Pharmaceuticals Struggles to Protect Star Drug Market Position

Pharmaceutical Network February 7th, Beida Pharmaceuticals Vice President and Sales Director Shen Haixuan, chief chemist Hu Weijing two key staff both left, weak revenue growth of Beida Pharmaceuticals more like thin iceEktini, the main product of Beida Pharmaceuticals, has entered the medical insurance payment list in 26 provinces and autonomous regions across the country, but that does not eliminate Beida Pharmaceuticals' troublesThe main competition Giifini, Elotini in China's patents have expired, a number of enterprises actively apply for Giifitini imitation, the endless competition is bound to split the market share of Beda Pharmaceuticals EktiniThe departure of two of's keybeta pharmaceutical executives has sparked much speculation in the industryBeida Pharmaceuticals announced that the company's former vice president and sales director Shen Haixuan resigned as vice president, Hu Yujing resigned as chief chemistAfter resigning, both men no longer hold other positions in the companyit is understood that Shen Haixuan is vice president and sales director of Beida Pharmaceuticals, mainly responsible for the company's product sales in the country, has previously served in GSK, Roche sales manager, sales director, BU directorHu Is the Chief Chemist of Beida Pharmaceuticals, he has more than 10 years of experience in the development of new drug development and intellectual property in theoncology, obesity and diabetes, central nervous and anti-inflammatory drugstwo executives who developed and sold the company's most important divisionas a pharmaceuticalcompany resigned at the same time three months after the company went public, sparking speculationSome analysts believe that the two people are not optimistic about the future of the company, in the company's development strategy and other directions are dividedthe founding team of Beida Pharmaceuticals each dedicated to supporting the key links of the enterprise Ding served as chairman of Beida Pharmaceuticals, President Wang Inxiang was also chief scientist, responsible for research and development, and Zhang Xiaodong, the former vice chairman, helped connect international cooperation and projects in the United States However, the current founding team has been distracted, Zhang Xiaodong gradually exited Beida's research and development and business operations, Wang Inxiang as chairman of Beijing Gascos New Drug Research and Development Co., Ltd (hereinafter referred to as "Gakos" ) part of the focus on Gascos The departureofs of the two executives have fuelled speculation of instability in The Pharmaceuticals' core team the proliferation of competitions
perhaps hedging the negative impact of executive departures, the announcement of executive resignations coincided with the announcement of Ektini's access to health insurance According to the announcement, the company's main product, Ektini, had entered the health insurance payment list in 26 provinces and autonomous regions as of January 26, 2017 Access to the health insurance catalog will be conducive to product sales, industry analysts believe that this announcement or "Shen Haixuan's departure will destroy the company's sales channels" speculation however, The company's earnings report showed a change of -10-10% in 2016, and access to the Medicare payment catalog did not appear to have brought substantial benefits to Ektini Ektini is the main source of income for Beda Pharmaceuticals According to a prospectus issued by Beda Pharmaceuticals in May 2016, 98 percent of the company's revenue comes from Ektini Beda Pharmaceuticals says Ektini will be the company's main source of revenue for the next three years unique, risk-resistant ability is bound to become the capital market's concern for the company It is understood that Ektini's main competitorgi giffeitini, Elotini in China's patents have expired, according to cFDA public information shows that as of August 31, 2016, there are 25 domestic companies in the application of Giffeitini imitation, 28 companies in the application for Erlotini imitation also, Ziru Pharmaceuticals' Giifinib has been listed, and the endless competition could threaten the market for Beda Pharmaceuticals' Ektini dilution of market share
Although Ektini's entry into the Health Care Payment Catalog can provide sales channels for Beda Pharmaceuticals, there is no denying that Beda's performance is weak and may even come under further pressure, and that Beda Pharmaceuticals is in desperate need of the next Ektini-like product data show that the Current Bayda Pharmaceuticals has a total of 22 research projects, of which 1.1 new drugs 5, 3 are anti-tumor drugs, except for one has been approved for clinical trials, the remaining 4 are in the preclinical research stage The new drug research and development cycle is long, there are analysis reports that Beida Pharmaceuticals will not have 1, 2 new drugs on the market until 2020, 2017-2019 at most, there are some 3, 4 generic drugs on the market And it also means that beda pharmaceutical revenue over the next three years is largely dependent on Ektini the departure of two executives would add to the woes of Beda Pharmaceuticals Shen Haixuan is directly responsible for the construction of sales channels of Beida pharmaceutical industry, Hu Yujing as the company's chief chemist, with a number of scientific research projects, leaving the company may lead to a large number of projects lag industry analysis, in the short term, Beida Pharmaceuticals has a heavy new drug out of the possibility is low, unless acquisitions or mergers And the talent of the founding team lost, or have some impact on the progress of research and development In addition, the proliferation of Ektini competitions may split the market for Beda Pharmaceuticals